March 4, 2021 – Philadelphia, PA – We are pleased to announce that Ms. Haiyan Liu will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Executive Director of Analysis and Testing.

Ms. Haiyan Liu will be leading WuXi ATU China Analytical Development and Quality Control to build a first-class testing center in China for CGT programs from clinical to commercial. Haiyan has over 21 year industry experiences in analytical development, quality control and CMC, and over 15 years of managerial experiences. Prior to joining WuXi ATU, Haiyan worked at GlaxoSmithkline, Bristol-Myers Scribb, bluebird bio, and Rubies therapeutics and held various positions with increased responsibilities in support of projects from IND to commercial stages in the areas of protein and cell therapeutics. Her teams were responsible for method development, transfer/validation, testing, investigation, change control, CAPA, specification, stability, and relevant regulatory submissions. Additionally, Haiyan has a proven record of implementation of new technologies and leading cross-functional teams.

Haiyan graduated from Xiamen University with a bachelor’s degree in Microbiology and University of North Texas with a master degree focusing on molecular biology and biochemistry.

We are excited to welcome Haiyan to WuXi Advanced Therapies!

About WuXi Advanced Therapies (ATU)
As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the development, testing, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit

Media Contact:
Min Park
Global Head of Marketing
WuXi Advanced Therapies